Healthy females, pregnant with a boy, generate immune responses against male-specific minor histocompatibility (HY) antigens. The clinical importance of these responses is evident in stem cell transplantation. Birth of a boy prior to a series of miscarriages reduces the chance of a subsequent live birth. This study explores the putative impact of known HY-presenting HLA alleles on future pregnancy outcome in women with at least three consecutive miscarriages following a birth [secondary recurrent miscarriage ( 
INTRODUCTION
The majority of pregnancies end with a live born baby. Apparently, the carriage of the fetal semi-allograft is tolerated by the maternal immune system. Analysis of pregnancies with putative absence of maternal tolerance of the fetus is difficult, since the majority of miscarriages are caused by chromosomal abnormalities (1) . This study is a first attempt to study the paradox of maternal tolerance based on a group of patients in whom an immunological background for their repeated pregnancy losses is highly suspected (2, 3) . All these patients are suffering unexplained secondary recurrent miscarriage (SRM). SRM is defined as a minimum of three consecutive miscarriages subsequent to the birth of a child. Among SRM patients, a boy prior to the series of miscarriages is significantly more common than a girl and also reduces the chance of a subsequent live birth among these patients (4, 5) .
Male-specific minor histocompatibility (HY) antigens are encoded by genes on the Y-chromosome. Generally, the minor H antigens HY are ubiquitously expressed in male cells including fetal and trophoblast cells (6) . Processed peptide fragments of the HY-proteins bind to HLA class I and class II molecules and are presented to the immune system. Studies using HLA class I-and II-restricted CD8þ and CD4þ T cell clones isolated from patients after HLA-matched sex-mismatched stem cell transplantation (SCT) revealed the molecular identification of a series of HY antigens and their respective genes (7) . In the non-physiological situation of SCT, male recipients of parous female HLA-matched stem cell grafts are more prone to develop GvHD than those of either nulliparous female grafts or male grafts, suggesting that previous pregnancy of the female stem cell donor can enhance GvHD after SCT (8, 9) . In the physiological situation of pregnancy, maternal immune recognition of the minor HY antigens from male fetuses is considered a well-tolerated status by the male fetus, as half of all newborns are healthy boys. However, a potential harmful role for these responses in pregnancy has been suggested as well; a population-based study reported that a history of previous birth of boys is associated with decreased birth weight of subsequent children (10) . Additionally, among patients with SRM, boys prior to the series of miscarriages are correlated with a subsequent lower live birth rate (4, 5) .
This study investigates whether or not SRM patients positive for one or more of the HLA alleles known to efficiently present HY peptides show different incidences of subsequent live birth than SRM patients negative for these HY-presenting HLA class I and II alleles.
RESULTS
In order to investigate whether or not the HY-restricting HLA alleles are associated with the pregnancy prognosis in the first pregnancy after referral in SRM patients, four different groups were analysed. The first group deals with maternal carriage of HY-restricting HLA class I alleles and subsequent pregnancy outcome. The second group deals with maternal carriage of HY-restricting HLA class II alleles and subsequent pregnancy outcome. The third group deals with the frequency of maternal carriage of HY-restricting HLA class II alleles and the fourth group deals with firstborn child carriage of HY-restricting HLA class I and class II alleles and subsequent pregnancy outcome.
Maternal carriage of HY-restricting HLA class I alleles and subsequent pregnancy outcome Carriage of HY-restricting HLA class I alleles did not impact the pregnancy prognosis by comparing patients with SRM with a firstborn boy with SRM patients with a firstborn girl. Neither did carriage of HY-restricting HLA class I alleles impact the pregnancy prognosis within the subgroups of SRM patients with firstborn boys and girls, respectively (Table 1) . Thus, no prognostic impact of maternal HY-restricting HLA class I alleles on the chance of a live birth in SRM patients was detected.
Maternal carriage of HY-restricting HLA class II alleles and subsequent pregnancy outcome in SRM patients with firstborn boys compared with firstborn girls Among the 286 patients who conceived after referral, maternal carriage of HY-restricting HLA class II alleles significantly reduced the chance of a live birth in patients with a firstborn boy compared with patients with a firstborn girl [odds ratio (OR): 0.17 (0.08 -0.4), P ¼ 0.0001 (Table 2) ]. Maternal carriage of the HLA-DRB1 Ã 15 or the HLA-DQB1 Ã 0501/0502 allele reduced the chance of live birth in those with firstborn boys compared with firstborn girls. Although the live birth rate was 29% lower in patients with firstborn boys carrying HLA-DRB3
Ã 0301 compared with those with firstborn girls, this allele did not significantly reduce the chance of a live birth. Among the patients without HY-restricting HLA class II alleles, the chance of a live birth was similar in those with firstborn boys (66%) and those with firstborn girls (69%) (P ¼ 0.76). Thus, the presence of maternal HY-restricting HLA class II alleles on the chance of a live birth in SRM patients with firstborn boys compared with girls may be of prognostic value.
Influence of one or more maternal HY-restricting HLA class II alleles on the chance of a live birth in SRM patients with firstborn boys
In patients with boys prior to the miscarriages, the influence of maternal carriage of HY-restricting HLA class II alleles on the outcome of the first pregnancy after referral was subsequently investigated. As shown in Table 3 , maternal carriage of one HY-restricting HLA class II allele reduced the OR for a live birth to 0.46 (0.2 -0.9) (P ¼ 0.02), whereas carriage of two (Table 3) . Thus, the presence of maternal HY-restricting HLA class II molecule significantly reduces the chance of a live birth in a dose -response manner among patients with firstborn boys.
Influence of maternal HY-restricting HLA class II alleles on the chance of a live birth in SRM patients with firstborn girls Maternal HY-restricting HLA class II did not negatively impact the pregnancy prognosis in patients with a firstborn girl; if anything, carriage of one allele tended to be protective, thereby increasing the chance of a live birth with an OR of 2.7 (1.0 -7.2) (P ¼ 0.06) ( Table 3) .
HY-restricting HLA class II allele frequency in SRM patients
The above-described association of HY-restricting HLA class II alleles in patients with recurrent miscarriages subsequent to the birth of a boy led us to question whether these HY-restricting HLA class II alleles would predispose to recurrent miscarriages. The allele frequencies of HY-restricting alleles in SRM patients with an uncomplicated firstborn male birth compared with firstborn female birth were, however, identical (P ¼ 0.47, Table 4 ).
Differences in HY-restricting HLA class II frequencies were only found for a subgroup of the patients, namely SRM patients with a complicated birth of a boy (stillbirth and/or birth weight ,2500 g) prior to the miscarriages than in SRM patients with a complicated birth of a girl (P ¼ 0.003, Table 4 ). Maternal HY-restricting HLA class II alleles were also significantly more present in complicated pregnancies compared with uncomplicated pregnancies with a boy (P ¼ 0.001). Regarding patients with firstborn girls, the opposite was found: maternal HY-restricting HLA class II alleles were significantly more common in women with uncomplicated compared with complicated pregnancies (P ¼ 0.05).
Firstborn child carriage of HY-restricting HLA alleles and subsequent pregnancy outcome in SRM patients with firstborn boys compared with firstborn girls
We analysed the influence of the HY-restricting HLA class I and class II of the firstborn child on their mother's subsequent chance of a live birth comparing firstborn boys with firstborn girls. Out of 203 HLA-typed children born prior to the miscarriages, 178 of the mothers became pregnant after referral. Child carriage of HY-restricting HLA class I alleles did not impact the pregnancy prognosis (data not shown). HY-restricting HLA class II alleles of the firstborn child significantly reduced the chance of a live birth in patients with firstborn boys compared with girls [OR: 0.28 (0.1 -0.7), P ¼ 0.007 (Table 5) ]. Limiting the above analysis to those 24 children, in which only the child but not the mother carries an HY-restricting HLA class II allele, no reduction in chance of a live birth was observed [OR 1.94 (0.3 -15), P ¼ 0.52 (Table 5) ]. Thus, the presence of the HY-restricting HLA class II alleles in firstborn boys as opposed to the firstborn girls might not influence the outcome of the subsequent pregnancy.
Influence of one or more child-specific HY-restricting HLA class II alleles on the chance of a live birth in SRM patients with firstborn boy and firstborn girls
Carriage of only one HY-restricting HLA class II allele in firstborn boys did not impact the pregnancy prognosis. Carriage of two HY-restricting HLA class II alleles in firstborn boys (mother necessarily positive) decreased the subsequent live birth rate to the same level as mothers carrying two HY-restricting HLA class II alleles [OR: 0.18 (0.0 -9.97), P ¼ 0.05 (Table 6) ]. No negative impact on pregnancy prognosis was found when limiting the analysis to those 12 boys, wherein only the child but not the mother carries the HY-restricting class II alleles (Table 6 ). If both the mother and the child carried HY-restricting HLA class II alleles, the chance of a live birth among mothers with firstborn boys was OR: 0.39 (0.2 -0.9) (P ¼ 0.02); whereas no influence is observed among mothers with firstborn girls (Table 6 ). Thus, the carriage of HY-restricting HLA class II alleles in firstborn boys and girls might not influence the success of the mother's next pregnancy. Maternal and firstborn child sharing the relevant HY-restricting HLA class II alleles did not seem to impact the pregnancy prognosis more than solely maternal carriage of the same alleles.
DISCUSSION
Maternal acceptance of the fetal semi-allograft is an immunological paradox. The majority of pregnancies end with delivery of a healthy child. Studying pregnancies with putative absence of maternal tolerance of the fetus is difficult as most pregnancy losses are due to chromosome abnormalities. An immunological role for the repeated pregnancy losses is, however, highly suspected in patients suffering SRM. Focusing on SRM patients, we here studied a possible influence of the patients' immunogenetic make up on the pregnancy outcome.
We studied the postulated influence of immunologically relevant anti HY-immune responses on the outcome of the patients' subsequent pregnancies. Here, the influence of the presence of the known HY-presenting HLA class I and class II alleles in both the mother and the child born prior to the miscarriages was investigated. Maternal carriage of HLA class I alleles known to restrict presentation of HY peptides was not found to be associated with the pregnancy prognosis in SRM patients with a firstborn boy. Interestingly, maternal Ã 0501/0502 reduced the ORs (P ¼ 0.0001) for a live birth when comparing SRM patients with firstborn boys with those with firstborn girls and also reduced the chance of a live birth in patients with firstborn boys. The live birth rate was 29% lower for SRM patients with firstborn boys carrying the HLA-DRB3
Ã 0301 allele compared with SRM patients with firstborn girls. This difference, however, did not reach statistical significance, which could be due to the low number of patients carrying this class II restricting allele. We conclude that maternal carriage of HLA class II alleles restricting anti-HY immunity is associated with a decreased pregnancy prognosis in SRM patients with a boy prior to a series of miscarriages, but not SRM patients with a firstborn girl.
The observation that HLA class II and not class I HY-restricting alleles impact the pregnancy prognosis might reflect the participation of CD4þ T cells providing help for the CD8þ cytotoxic T cells in their response against minor H antigens. Indeed, the presence of CD4þ T cells with antirecipient activity rather than CD8þ T cells was earlier reported in association with GvHD (11 -13). The absence of association with HLA class I HY-presenting alleles and pregnancy outcome in our study must, however, be drawn with care since only 15% of all women included in this study were negative for any HY-restricting HLA class I allele. More patients need to be analysed to underline these first indications of absence of impact of HY-restricting HLA class I alleles.
The association of pregnancy outcome with maternal carriage of HY-restricting HLA class II alleles may imply that the class II-restricted HY-antigens are presented to the immune system via the indirect pathway (maternal HLA class II alleles present fetal HY-antigens). Evidently, the direct presentation of HY-peptides by the male fetus may be active as well. Hereto, HLA-typing of the children born prior to the series of miscarriages was possible for 64% of the children. The sole effect of child carriage HY-restricting HLA class II alleles was analysed in two ways. First, we found similar OR for live birth when the mother and the child shared the HY-restricting HLA class II alleles compared with when the mother had one HY-restricting HLA allele. Secondly, although only limited numbers could be analysed, no decrease in the live birth rate was found if only the firstborn child and not the mother carried HY-restricting HLA class II alleles. Only firstborn boys being homozygous for the HY-restricting HLA class II alleles (mother also positive) significantly influenced future pregnancy outcome in SRM patients. Our data point to the involvement of mainly the indirect pathway of HY-antigen presentation. The latter as well as the impact of HY-restricting HLA class II alleles of the child born prior to the miscarriages needs further exploring.
We operationally defined HY-restricting HLA alleles as those class I and class II alleles reported to date to restrict presentation of HY-antigens. Given the high degree of HLA polymorphism in combination with the number of HY proteins, one would expect more HLA class I and II alleles presenting the various HY-antigens. Our definition can thus not be considered exhaustive, and identification of other HY-restricting HLA alleles may alter our results. It might, however, be that the HY-restricting HLA class II alleles are limited or that the currently identified HY-presenting class I and class II alleles are the dominant ones (7, 14) . Moreover, these first analyses comprising the so-far identified HY-restricting HLA class II alleles only associate with pregnancy outcome in SRM patients with firstborn boys, but not in patients with firstborn girls. Finally, live birth rates in SRM patients with firstborn boys carrying no HY-restricting HLA class II alleles are nearly identical to those SRM patients with no HY-restricting HLA class II and firstborn girls.
We observed that maternal carriage of HLA-DQB1 Ã 0501/ 0502 significantly reduces the odds for a live birth, whereas carriage of HLA-DQB1
Ã 0503 was associated with increased chance of a live birth. This observation is most likely the result of the fact that DQB1
Ã 05-restricted peptide can be presented by the DQB1 Ã 0501 and DQB1 Ã 0502 alleles, but not by the DQB1 Ã 0503 allele. This phenomenon is supported by an in vitro study (15) . This study demonstrated selective recognition by three different HY-specific T cell clones against HLA-DQB1
Ã 0501-and DQB1 Ã 0502-positive without reactivity against HLA-DQB1
Ã 0503-and DQB1 Ã 0504-positive Epstein -Barr virus-transformed B lymphoblastoid cell lines transfected with relevant HY-genes. Our clinical observation and Laurin's in vitro data can be explained by molecular differences in these alleles. The DQB1 Ã 0501, 0502, 0503 differ at position 57. This position is situated on the alpha helix that contributes to the peptide specificity of the DQB1 Ã 05 alleles. The amino acids are V, S, D for the respective alleles. Apparently, the V!S substitution does not affect binding of this particular peptide, whereas introduction of a charged amino acid does. As for the DQB1 Ã 0504 allele, we could not confirm the previous observations, as the frequency of this allele in our population is very low (1/750) and none of our patients carried that allele.
The underlying mechanism of our epidemiological finding that maternal carriage of HY-restricting HLA class II alleles significantly reduces the chance of a live birth in SRM patients with a firstborn boy can be 2-fold. First, HY-immunization may have taken place during the first ongoing pregnancy with a boy. Maternal immune recognition of HY-antigens can be demonstrated in women following pregnancies with boys (16, 17) . As half of all pregnancies involve male fetuses, these responses must, in general, be well tolerated. HY-immunization may also have harmful effects as indicated in the non-physiological setting of SCT leading to increased GvHD and transplant-related mortality when the donors are parous females (18 -21) . In late pregnancy, apoptotic syncytiotrophoblast debris is normally shed in large quantities (several grams per day) from the placenta (22,23); after being processed by macrophages, it is taken up by maternal dendritic cells located at the feto -maternal interface and transported to local lymph nodes. Here, intracellular proteins such as HLA class II and HY-antigens are presented to CD4þ and CD8þ T lymphocytes (22) . This presentation usually takes place under non-inflammatory conditions, resulting in T lymphocytes being tolerized against fetal minor H antigens and HLA molecules (24) . Late pregnancy complications such as stillbirth or fetal growth retardation occurred in 18% of the pregnancies with boys prior to the series of miscarriages. These complications are associated with increased maternal production of inflammatory cytokines systemically or locally in uterus (25 -27) and increased shedding of apoptotic trophoblast cells (28) . We hypothezise that the risk of sensitization is further increased in those patients carrying the HY-restricting HLA class II alleles.
Secondly, microchimerism might be another explanation for our findings of the postulated negative prognostic impact of HY-restricting HLA class II alleles in patients with recurrent miscarriage after the birth of a boy. Microchimerism, the co-existing of various amounts of fetal cells years after pregnancy, is a well-described phenomenon (29 -31) . Fetal microchimerism is found to be associated with fetal losses (31) , and increased amount of fetal cells in the maternal circulation is found in pre-eclampsia (32 -34) , pre-term labour (35) and stillbirth (36) . Accordingly, relative high quantities of fetal microchimerism may be suspected in the SRM patients, leading to significant engraftment of cells and self-renewing stem cell progenitors from the firstborn boy. This may potentially lead to an unbalance in the mother's anti-HY T cell activities favouring cytotoxic and not regulatory T cells.
The present study documents a strong association of the known HY-restricting HLA class II alleles and pregnancy outcome in SRM patients with firstborn boys but not in SRM patients with firstborn girls. Live birth rates in SRM patients carrying no HY-restricting HLA class II are almost identical for those with firstborn boys compared with those with firstborn girls. The study was executed in a large cohort of thoroughly investigated and otherwise unexplained SRM patients with complete follow-up of 5 months to 21 years, covering the geographical area of a whole country. We postulate that HY-restricting HLA class II alleles in the mother reduce the chance of a successful pregnancy in patients with recurrent pregnancy losses subsequent to a boy. These results are the first in its kind and may shed light on the as-yet unknown immunological causes of pathophysiological mechanisms in this disease and may also help understand the successful maternal acceptance of the fetal semi-allograft.
MATERIALS AND METHODS

Patient selection
Recurrent miscarriage is defined as a minimum of three consecutive losses of intrauterine pregnancies before the 22nd gestational week. Women with at least one pregnancy of minimum 22 weeks gestation prior to the series of pregnancy losses were diagnosed as having SRM. All reported pregnancies were confirmed by a positive urine or serum-hCG pregnancy test, ultrasonic examination and/or histology of aspirated tissue from the uterus, documented in the hospital's or practitioner's records. The recurrent miscarriages were considered to be unexplained if the woman had normal uterine anatomy evaluated by hysterosalpingography, hysteroscopy or saline hydrosonography; their menstrual cycles were regular with 21-35-day' intervals; they were negative for the lupus anticoagulant investigated as previously described (37) and the couples had normal karyotypes.
The study included patients with unexplained SRM and (in case of more than one previous child) preceding children Blood was taken for DNA preparation and storage from all patients at the initial consultation. The following information was also provided at the initial consultation regarding the child born prior to the miscarriages: sex of the child, live or stillborn child, birth weight and gestational week. Patients referred after year 2003 were asked to participate in this study at their initial consultation, whereas patients referred from 1986 to 2003 were asked by mail. We asked for permission to do full HLA typing on the stored maternal DNA and to obtain DNA from the firstborn child. A first and second reminder was sent to those women or children who did not respond to this query. A total of 35 SRM patients were excluded as they had children of different sexes prior to the series of miscarriages; two patients were excluded due to failed HLA typing of maternal DNA. Background details on the included women are shown in Table 7 .
Women who agreed to participate were given and instructed in using a DNA buccal swap for HLA-typing of the child born prior to the series of miscarriages. The buccal swap was in most instances taken by the parents and returned immediately to the clinic. For offspring of 18 years or older, we asked the mother for permission to contact him/her directly. Children of 203 women were HLA-typed; 40 refused typing, whereas seven women had emigrated and 81 did not react to the query. Twenty-seven of the children born prior to the miscarriages were stillborn, and HLA-typing was accordingly not feasible.
Information about pregnancy outcome in the first pregnancy after referral was collected as described previously (4, 5) . Among the 358 patients with SRM included in this study, 286 became intrauterine pregnant after referral. One hundred and eighty-one (63%) of these pregnancies ended in a live birth, whereas 105 (37%) miscarried again. The miscarriage rate in the first pregnancy was 46% in SRM patients with a firstborn boy and 24% in those with a firstborn girl (P , 0.0001).
HY-restricting HLA
The term 'HY-restricting HLA' is used to describe those HLA alleles reported to date that functionally present HY peptides. 
HLA typing
HLA-A, -B, -DRB1, -DRB3, -DRB4, -DRB5 and -DQB1 typing was performed using The Luminex xMAP system, a multiplexed microsphere-based suspension array platform for highthroughput nucleic acid detection and LABType SSO, a reverse SSO DNA typing system (One Lambda Inc., Canoga Park, CA, USA) according to the instructions from the manufacturers.
Statistical analysis
Data were managed by Access 9.0.2719 (Microsoft), and SPSS 15.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. The analyses included x 2 -test, Fisher's exact test and the Mann -Whitney U-test to determine differences in background data and obstetric complications in the pregnancy prior to the miscarriages. The impact of HY-restricting HLA class I and II alleles on subsequent pregnancy outcome was tested separately in logistic regression analyses with live birth in the first pregnancy following referral as the outcome variable. The analysis was adjusted for a number of previous miscarriages entered as a continuous variable.
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